TOP TEN perturbations for 1553077_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553077_at
Selected probe(set): 1553077_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553077_at (1553077_at) across 6622 perturbations tested by GENEVESTIGATOR:

split-thickness skin grafting study 1 / normal skin tissue (skin grafting)

Relative Expression (log2-ratio):-3.6848269
Number of Samples:6 / 8
Experimental split-thickness skin grafting study 1
Skin punch biopsy from patients with skin injury (burn injury, congelation, wound, compartment syndrome) immediately after split-thickness skin grafting was done. Sample was taken from the acute wound after grafting.
Control normal skin tissue (skin grafting)
Skin biopsy samples from healthy control subjects after breast or abdomen reduction surgery.

psoriasis study 11 (lesional; brodalumab; 15d; 700mg) / psoriasis study 11 (lesional; baseline)

Relative Expression (log2-ratio):-3.3613515
Number of Samples:8 / 25
Experimental psoriasis study 11 (lesional; brodalumab; 15d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; baseline)
Lesional skin punch biopsy samples derived from patients with moderate to severe plaque psoriasis before treatment.

skin transplantation study 1 (7d) / split-thickness skin grafting study 1

Relative Expression (log2-ratio):3.0586166
Number of Samples:5 / 6
Experimental skin transplantation study 1 (7d)
Human skin punch biopsy from patients after skin grafting. Sample was taken at the site of re-epithelialization 7 days after surgery.
Control split-thickness skin grafting study 1
Skin punch biopsy from patients with skin injury (burn injury, congelation, wound, compartment syndrome) immediately after split-thickness skin grafting was done. Sample was taken from the acute wound after grafting.

psoriasis study 11 (lesional; brodalumab; 43d; 700mg) / psoriasis study 11 (lesional; baseline)

Relative Expression (log2-ratio):-2.7769394
Number of Samples:8 / 25
Experimental psoriasis study 11 (lesional; brodalumab; 43d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 43 (week 6) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; baseline)
Lesional skin punch biopsy samples derived from patients with moderate to severe plaque psoriasis before treatment.

Merkel cell carcinoma study 3 (metastatic) / normal skin tissue

Relative Expression (log2-ratio):-2.7593355
Number of Samples:11 / 64
Experimental Merkel cell carcinoma study 3 (metastatic)
Metastatic tumor tissue from different metastatic sites (skin, lymph node, parotid gland) of patients with Merkel cell carcinoma of the skin.
Control normal skin tissue
Normal skin samples from healthy donors.

psoriasis study 11 (lesional; brodalumab; 43d; 700mg) / psoriasis study 11 (lesional; placebo; 43d)

Relative Expression (log2-ratio):-2.7318916
Number of Samples:8 / 4
Experimental psoriasis study 11 (lesional; brodalumab; 43d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 43 (week 6) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; placebo; 43d)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 43 (week 6) after treatment with placebo.

Merkel cell carcinoma study 3 (primary) / normal skin tissue

Relative Expression (log2-ratio):-2.6744328
Number of Samples:19 / 64
Experimental Merkel cell carcinoma study 3 (primary)
Primary tumor tissue from the skin of patients with Merkel cell carcinoma.
Control normal skin tissue
Normal skin samples from healthy donors.

psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; non-responder) / psoriasis study 24 (non-lesional; baseline; ustekinumab; 90mg; non-responder)

Relative Expression (log2-ratio):2.598319
Number of Samples:10 / 9
Experimental psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 90 mg ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 24 (non-lesional; baseline; ustekinumab; 90mg; non-responder)
Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 90 mg ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

skin transplantation study 1 (3d) / normal skin tissue (skin grafting)

Relative Expression (log2-ratio):-2.5913754
Number of Samples:6 / 8
Experimental skin transplantation study 1 (3d)
Human skin punch biopsy from patients after skin grafting. Sample was taken at the site of re-epithelialization 3 days after surgery.
Control normal skin tissue (skin grafting)
Skin biopsy samples from healthy control subjects after breast or abdomen reduction surgery.

psoriasis study 25 (lesional; baseline; ustekinumab; non-responder) / psoriasis study 25 (non-lesional; baseline; ustekinumab; non-responder)

Relative Expression (log2-ratio):2.5473328
Number of Samples:10 / 9
Experimental psoriasis study 25 (lesional; baseline; ustekinumab; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 25 (non-lesional; baseline; ustekinumab; non-responder)
Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT.